The prognosis for elderly patients with diffuse large B-cell lymphomas (DLBCL) remains particularly poor. The most common explanation involves co-morbidities related to advanced age, which strongly impact chemotherapy feasibility and tolerance.[1][1] Despite a generally poor prognosis, a recent
No takes yet. Share an insight, caveat, or question.
Mareschal et al. (2011) studied this question.